-
ChaC1-Driven Drug Screening Unveils Synergy for HCC Therapy
2026-05-13
This study pioneers a ChaC1-based pharmacological screening strategy to identify synthetic lethal interactions in hepatocellular carcinoma (HCC), revealing that glutathione depletion via ChaC1 sensitizes HCC cells to combined auranofin and proteasome inhibitor treatment. The findings offer a mechanistically rational drug repurposing framework with translational potential for HCC therapy.
-
Recombinant Mouse Sonic Hedgehog: Precision for Genital Deve
2026-05-13
Explore how Recombinant Mouse Sonic Hedgehog (SHH) protein enables rigorous, species-specific investigation of genital development and urethral patterning. Unpack mechanistic insights and practical assay guidance not found in existing content.
-
Topotecan (SKF104864): Optimizing Cancer Research Workflows
2026-05-12
Topotecan (SKF104864) stands out as a semi-synthetic camptothecin analogue and potent topoisomerase I inhibitor, delivering consistent apoptosis induction and cell cycle arrest in both glioma and pediatric solid tumor models. This article translates the latest clinical and translational evidence into practical workflows and troubleshooting strategies for advanced cancer research applications.
-
Applied Workflows with Bortezomib (PS-341) in Cell-Based Ass
2026-05-12
Leveraging Bortezomib (PS-341) from APExBIO enables precise, reproducible interrogation of proteasome-regulated cellular processes and apoptosis in oncology and neurodegeneration models. This guide bridges experimental workflows, advanced troubleshooting, and the latest evidence on proteasome inhibition to maximize your research impact.
-
TACE Silencing in Visceral ATMs: A Targeted Approach to Obes
2026-05-11
This study demonstrates a novel, non-viral gene delivery strategy that selectively targets visceral adipose tissue macrophages (ATMs) using the ATS-9R peptide for TACE gene silencing. The approach effectively reduces obesity-associated inflammation and improves insulin resistance in obese mouse models, highlighting a precise tool for metabolic disease research.
-
Patient-Derived 3D Spheroids: A Translational Model for Pros
2026-05-11
This study establishes and characterizes patient-derived, three-dimensional spheroid cultures from radical prostatectomy tissue as a robust, organ-confined prostate cancer (PCa) model. The innovation enables long-term, physiologically relevant in vitro studies—including drug response profiling—in a context that recapitulates native tumor microarchitecture, offering practical advances for preclinical research and therapeutic discovery.
-
Redefining In Vitro Metrics for Anti-Cancer Drug Evaluation
2026-05-10
Schwartz’s dissertation clarifies the distinction between proliferative arrest and cell death in in vitro drug response assays, highlighting the necessity of measuring both to accurately interpret anti-cancer efficacy. These insights guide improved assay design and data interpretation, with direct implications for evaluating agents like JNJ-26854165 (Serdemetan) in preclinical research.
-
Refining In Vitro Drug Response Metrics in Cancer Research
2026-05-09
Schwartz (2022) introduces a critical framework for evaluating anti-cancer drug responses by distinguishing between relative and fractional viability in vitro. This innovation clarifies the distinct mechanisms of growth inhibition and cell death, shaping more precise experimental interpretation and future assay design.
-
Fluconazole as a Fungal Cytochrome P450 Enzyme Inhibitor in
2026-05-09
Fluconazole, a potent fungal cytochrome P450 enzyme 14α-demethylase inhibitor, underpins reproducible antifungal susceptibility testing and advanced Candida albicans infection models. Explore protocol enhancements, troubleshooting insights, and novel host-pathogen interaction assay designs that maximize discovery potential with APExBIO’s trusted reagent.
-
Inhibition of Renal OCT2 and MATE1 by 5-HT3 Antiemetics: Mec
2026-05-08
This study systematically evaluates how commonly used 5-HT3 antagonist antiemetic drugs inhibit renal organic cation transporters OCT2 and MATE1 in vitro. The findings clarify potential drug-drug interactions affecting renal secretion of cationic drugs, with significant implications for pharmacokinetics and clinical practice.
-
SGI-1027: Applied Workflows for DNA Methyltransferase Inhibi
2026-05-07
SGI-1027 empowers cancer epigenetics research with robust, Ado-Met competitive DNA methyltransferase inhibition, enabling reproducible tumor suppressor gene reactivation. This guide translates recent methodological advances and real-world troubleshooting into actionable protocols, maximizing the impact of SGI-1027 in experimental epigenetics.
-
U 46619: Mechanistic Precision for Translational Platelet &
2026-05-07
This thought-leadership article bridges advanced mechanistic insights on U 46619 (11,9 epoxymethano-prostaglandin H2) with actionable strategic guidance for translational researchers. Leveraging the latest quantitative and functional evidence, it elucidates U 46619's role as a selective platelet aggregation inducer and vascular modulator, while offering protocol-driven parameters and workflow recommendations. The discussion integrates peer-reviewed findings on direct thrombin inhibitors like dabigatran, situating U 46619 within the evolving landscape of experimental cardiovascular research. APExBIO’s U 46619 is positioned as a benchmark tool for robust, reproducible platelet and vascular assays, empowering researchers to generate clinically relevant data and accelerate translational impact.
-
α-KG Restores Mitochondrial Function and Delays HPDLSC Senes
2026-05-06
This study reveals how α-ketoglutarate (α-KG) counteracts mitochondrial dysfunction and premature senescence in human periodontal ligament stem cells (HPDLSCs) under inflammatory conditions via the LKB1-AMPK pathway. The findings offer mechanistic insights and propose α-KG as a promising strategy for periodontal regeneration in chronic periodontitis.
-
Improving In Vitro Drug Response Evaluation in Cancer Resear
2026-05-06
This dissertation introduces a refined approach to evaluating anti-cancer drug responses by differentiating between proliferative arrest and cell death in vitro. The study demonstrates that common metrics often conflate these effects, and that precise measurement enables better prediction of therapeutic efficacy and mechanistic insight for agents like JNJ-26854165 (Serdemetan).
-
Bobcat339: Reliable TET Inhibition for Epigenetics Assays
2026-05-05
This article addresses common laboratory challenges in DNA methylation regulation and gene transcription modulation, focusing on the practical application of Bobcat339 (SKU BA4643) as a cytosine structure-based TET enzyme inhibitor. Using real-world scenarios, we demonstrate how Bobcat339 delivers reproducible results and enhances workflow reliability for biomedical researchers and lab technicians.